Below are upcoming trade shows and conferences that AnaBios will be attending. Be sure to check back often to view our upcoming events. Want to schedule a meeting with an AnaBios representative? Email us at

WEBINAR | Using Single Cell Sequencing to Identify Distinct Cell Populations from Fibrotic Tissue

APRIL 29, 9am PST

Join us on April 29th as Dr. Scott MacDonnell, Associate Director of Cardiovascular and Fibrosis Research at Regeneron Pharmaceuticals, presents our next webinar focusing on the use of single cell sequencing to identify cell populations from fibrotic tissue. Dr. MacDonnell and his team used an unbiased single cell RNA-sequencing analysis of a bleomycin-induced pulmonary fibrosis model to characterize molecular responses to fibrotic injury. Lung cells were isolated to capture emerging fibrosis and gene expression was analyzed by three complementary techniques which together generated a 49-gene signature that defined an activated subpopulation of fibroblasts. However, none of the identified genes were specific to the activated cells or disease setting, implying that the activated fibroblasts are not uniquely defined but exhibit a similar—yet amplified—gene expression pattern to control cells. Dr. MacDonnell will also discuss the implications of these findings. Click here to register for his webinar. 

WEBINAR | The Role of BAG3 in Dilated Cardiomyopathy

MAY 13, 8am PST

Join us May 13th for our next webinar about the role of BAG3 in dilated cardiomyopathy, presented by Dr. Arthur Feldman, Professor of Medicine at Temple University. Dilated cardiomyopathy (DCM) is a condition affecting more than 3 million US patients, many of whom develop DCM due to ischemic heart disease. Recently, subpopulations have been identified that develop DCM due to mutations in specific genes that have been shown to result in the development of DCM—one of those being the BAG3 gene. It is estimated that approximately 35,000 individuals in the United States have the disease-causing BAG3 haploinsufficiency, representing an orphan disease by FDA guidelines. Despite improvements in pharmacotherapy and care, the five year survival rate of a patient with DCM is only 50%. Dr. Feldman will discuss how the development of a BAG3 gene replacement therapy for patients with DCM that carry BAG3 mutations could potentially prevent progression of the disease in this otherwise healthy population of young adults. Dr. Feldman is an internationally renowned cardiologist who served as Executive Dean of the Temple University School of Medicine from 2011-2016. In 2016, he returned to the laboratory full-time and founded Renovacor Inc., a biotech company developing gene therapy for mono-genic causes of heart failure. Click here to register for his webinar. 

AnaBios Translational Research Award Grant

JUNE 30, 2021

AnaBios is awarding a US $15,000 Translational Research Grant to a research recipient to access our high-quality human tissue samples for their translational research project. In addition, AnaBios will award a 25% discount to the 10 highest ranked applications for the future purchase of AnaBios tissue samples. To view more information about the research grant, please click here.